Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBIT Margin (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed EBIT Margin for 6 consecutive years, with 3409.82% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 231765.0% to 3409.82% in Q4 2025 year-over-year; TTM through Dec 2025 was 891.07%, a 33526.0% decrease, with the full-year FY2025 number at 891.07%, down 33526.0% from a year prior.
  • EBIT Margin was 3409.82% for Q4 2025 at Kymera Therapeutics, down from 3347.32% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 40.33% in Q4 2023 to a low of 3409.82% in Q4 2025.
  • A 5-year average of 847.85% and a median of 426.88% in 2022 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: skyrocketed 29809bps in 2021, then tumbled -231765bps in 2025.
  • Kymera Therapeutics' EBIT Margin stood at 133.54% in 2021, then plummeted by -79bps to 239.36% in 2022, then soared by 83bps to 40.33% in 2023, then plummeted by -2608bps to 1092.17% in 2024, then plummeted by -212bps to 3409.82% in 2025.
  • Per Business Quant, the three most recent readings for KYMR's EBIT Margin are 3409.82% (Q4 2025), 3347.32% (Q3 2025), and 736.82% (Q2 2025).